, Volume 20, Issue 3, pp 103–107

Inflammation in neurological and psychiatric diseases

Inflammation in acute and chronic neurological and psychiatric diseases

DOI: 10.1007/s10787-012-0124-x

Cite this article as:
Khansari, P.S. & Sperlagh, B. Inflammopharmacol (2012) 20: 103. doi:10.1007/s10787-012-0124-x


In recent years, compelling evidence suggests that inflammation plays a critical role in the pathology of a vast number of neurological diseases such as stroke, Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis as well as neuropsychiatric diseases such as major depression and schizophrenia. Despite emerging evidence in human and animal models alike, modulating inflammatory responses have yet to be proven as an effective treatment to prevent or delay the progression of these diseases. The primary focus of this special edition is to highlight some of our current findings on the complexities of targeting neuroinflammation as a novel therapy, and its role in neurological and psychiatric disorders.


NeuroinflammationPsychiatric diseasesStrokeAlzheimer’s diseaseParkinson’s diseaseMajor depressionSchizophreniaAcute neurological diseasesChronic neurological diseasesAstrocytesMicrogliaPro-inflammatory cytokinesNSAIDs

Copyright information

© Springer Basel AG 2012

Authors and Affiliations

  1. 1.California Northstate University College of PharmacyRancho CordovaUSA
  2. 2.Laboratory of Molecular Pharmacology, Institute of Experimental MedicineHungarian Academy of Sciences (IEM HAS)BudapestHungary